– Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes – Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results